RC
CALA

RBF Capital’s Calithera Biosciences, Inc CALA Stock Holding History

RBF Capital’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-650
Closed -$55K – 385
2016
Q4 		$55K Buy
+650
New +$40.6K 0.01% 359

Other funds holding CALA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

RBF Capital's CALA Position: Q1 2017 in Review

RBF Capital sold out of Calithera Biosciences, Inc (CALA) in Q1 2017, closing a stake of 650 shares — an estimated $55K sold.

RBF Capital first reported a position in CALA in Q4 2016 and held it in 1 quarter. The position peaked at $55K in Q4 2016. 74 funds tracked by Wall St. Rank hold CALA as of Q1 2017.

  • RBF Capital reported no remaining Calithera Biosciences, Inc position as of Q1 2017 after selling out during the quarter.
  • RBF Capital sold 650 Calithera Biosciences, Inc shares in Q1 2017, an estimated $55K.
  • RBF Capital first reported a position in Calithera Biosciences, Inc in Q4 2016 and held it in 1 quarter.
  • RBF Capital's Calithera Biosciences, Inc position peaked at $55K in Q4 2016.
  • 74 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2017.

Based on RBF Capital's 13F filing for Q1 2017, filed 15 May 2017.